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Background: Supratentorial primitive neuroectodermal tumors (sPNET) are rarely occurred in adults. Only 39 cases have
been reported in the past decade. The transformation from low grade to aggressive astrocytoma is well known. However,
such convert from a low-grade astrocytoma (LGA) into a sPNET between two completely different tumors is rarer.
Case Presentation: This report discussed a 36-year-old male, who presented with the chief complaint of partial
seizures and left limbs dysfunction and Magnetic resonance imaging (MRI) of whom revealed right frontal lesions
which was operated to resect accompanied by the histological diagnosis of sPNET. The patient underwent operation
2.5 years ago because of seizures and was diagnosed with right frontal astrocytoma confirmed by pathology. However,
radiotherapy was not preformed on him after the primary surgery. Histology now revealed high grade PNET.
Conclusion: It is exactly uncertain that reports revelant to transformation from low-grade astrocytoma to a new kind of
tumor or neoplasm induced by radiotation have been published. This case report is accompanied by a review of 39
cases of adult sPNET in the past decade, especially discussing about the transformation of low grade glioma into sPNET.
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Primitive neuroectodermal tumor of the central nervous
system (CNS) described by Hart and Earle in 1973 [1] is
embryonal tumors composed of undifferentiated neuro-
epithelial cells which are capable of both glial and neur-
onal differentiation. The definition based on the
morphology is focused on small, blue round cells with a
high nuclear-cytoplasmic ratio exhibiting frequent mi-
tosis, apoptosis and neuronal marker positivity. Supra-
tentorial primitive neuroectodermal tumor (sPNET) is
defined as a cerebrum or suprasellar embryonal tumor
made up of undifferentiated or poorly differentiated
neuroepithelial cells which have the capacity for display-
ing divergent differentiation along neuronal, astrocytic,* Correspondence: weimingh@sina.cn; dyeyDr_yin@163.com
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the World health Organization (WHO) [2]. Although
PNET accounts for 2.8 % of all primary cerebral tumors
of childhood and adolescence [3], PNETs are extremely
rare in adults, representing less than 0.5 % of all intra-
cranial tumors [4]. So far only 39 such cases have been
previously reported in the past decade.
Case presentation
A 36-year-old male who had a 2-month history of tonic-
clonic seizures and 2.5-year history of headache con-
sulted an Epilepsy center. According to his medical his-
tory, a right frontal lobe lesion was resected 2.5 years
ago in another hospital, and the pathologically diagnose
was diffuse astrocytoma (WHO II) (Fig. 2a) while the ad-
juvant radio-chemotherapy was not performed.
Although oxcarbazepine had been taken in to control
epilepsy, he still presented with increased seizure fre-
quency, alongside with gradual dizziness and liability tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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deficit of left limbs and muscle weakness had been de-
tected through physical examination. The MRI revealed
recurrence of tumor located in right frontal lobe, which
was iso-low-intense on T1 weighted images, high-
intense on T2 weighted images, but MRI also showed a
mixed-anomaly signal in both T1WI and T2WI, which
was composed of cyst fluid surrounded by brain tissues
(Fig. 1a, b). It demonstrates enhancement within tumor,
which appears enlarged (Fig. 1c). During the craniotomy,
the dura matter was found to be normal, while the sur-
face of the brain was found to be deep yellow. Along the
tissue of cerebral surface resection, the old cystic fluid
was found and removed. The tumor was subtotal
resected.
Histologically, this tumor was confirmed to be a
typical diffuse astrocytoma (Fig. 2a) after the first sur-
gery, which was in a prominent microcystic back-
ground from the H&E stain. The recurrent tumor
was hypercellular with small round cells containing
hyperchromatic nuclei and a high nucleo-cytoplasmic
ratio (Fig. 2b). There were many cells with irregular
nuclei. The tumor cells were negative for argyrophil
fibers stain, but the Homer-wright (Fig. 2b, c) can be
detected distinctly. According to an immunohisto-
chemical analysis, the tumor was reactive to CD99
(Fig. 2d), glial fibrillary acidic protein (GFAP) (Fig. 2e),
synaptophysin (Fig. 2f ), neuron specific enolase
(Fig. 2g), Vimentin (Fig. 2h), CD56 (N-CAM) (Fig. 2i),
The tumor was thus diagnosed to be sPNET [5] with
glial, mesenchyimal, neuronal differentiation. The Ki-
67 index was about 17 %. The tumor was negative
for Oligo-2, AE1/AE3 and S-100. Based on these find-
ings, this tumor was diagnosed to be supratentorial
central PNET. The patient did not get any radiother-
apy or chemotherapy [6] on account of the low grade
astrocytoma. But the recurrent tumor was PNET
(WHO IV) [7]. Radiographic follow-up for 5 month
showed no evidence of recurrence.Fig. 1 MRI scan with contrast: a T1WI, b T2WI, c enhancement: iso-low- int
but MRI also showed a mixed-anomaly signal in both T1WI and T2WI, which
within tumour, which appears enlargedDiscussion
PNETs comprise a heterogeneous group of malignant tu-
mors that mainly affect the pediatric population, which
are composed of neuroepithelial cells that are able to dif-
ferentiate along the neuronal, astrocytic, muscular, or
melanocytic lines, with high index of proliferation [8].
Supratentorial PNETs are very rare and aggressive
tumors (WHO IV), and account for approximately 2.5–
3 % of all pediatric tumors [9]. LGA in adults are pri-
mary (CNS) neoplasms with a variable biological behav-
iour. While some remain dormant for several years,
others grow slowly, infiltrating surrounding normal
brain and showing an intrinsic tendency for transform-
ation into a higher grade astrocytoma [10].
Generally, adult PNETs usually appear as lobulated,
purple-grayish or pinkish masses. On microscopic exam-
ination, the tumor cell population consists of undifferen-
tiated small cells with ill-defined, scanty cytoplasm, and
round or oval cells with hyperchromatic nuclei [11]. Mi-
totic activity is variable. Microscopic calcifications, ne-
croses and Homer-Wright rosettes are also observed in
a number of cases. This article summarize a total of 40
cases of PNET in the past decade, most pathological
diagnosis is confirmed by tumor cell morphology. Path-
ology revealed sPNET that was characterized by dense
cellularity, marked nuclear pleomorphism, nuclear mold-
ing, brisk mitotic activity, and abundant apoptotic cell
death. The sPNET is diagnosed by Homer-Wright ro-
settes of morphological and immunohistochemical posi-
tive expression such as CD99 and GFAP, Syn, CD56
which alleviate the diagnostic rate. The Ki-67 index is an
important basis of pathological diagnosis.
Nowdays, the genetic and biological features of
pediatric PNETs are becoming more and more popular.
There are several theories that have been postulated to
describe the pathogenesis of radiogenic tumors: (a) radi-
ation could cause genetic alterations by disrupting the
deoxyribonucleic acid (DNA) of specific genes, such as
PTEN or the p53 tumor suppressor gene [12, 13]; (b)ense on T1 weighted images, high- intense on T2 weighted images,
was composed of cyst fluid surrounded by brain tissues, enhancement
Fig. 2 Histopathologic and immunohistochemical features in this case of adult PNETs.: a a diffuse astrocytoma: a prominent microcystic
background from the H&E stain. b Homer-Wright rosettes. c Tumors were mainly composed of undifferentiated tumor cells, with hyperchromatic
nuclei. d CD99 (+). e GFAP(+). f synaptophysin(+). g NSE(+). h Vimentin(+). i CD56(N-CAM) (+)
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multiple chromosome aberrations [14]; (c) irradiation
may induce the release of oncogenic factors, such as
platelet-derived and vascular endothelial growth factors
[15], beta chain of fibroblast growth factor [16], and
raised tissue level of basic fibroblast growth factor [17]
by alterating vascular parenchymal. In a patient with
radio-induced glioma reported by Gessi et al. [18], the
genetic alterations were p53 mutation, in which the
loss of heterozygosity of 17p and 19q, and O6-
methylguanine-DNA methyl-transferase (MGMT) pro-
moter methylation occurred, and without amplification
of epidermal growth factor receptor (EGFR). An unusual
somatic p53 mutation of a type specific to radiation-
induced DNA damage in a secondary glioblastoma iden-
tified by Tada [12]. Also IL-1βm-RNA was seven-fold
higher in the recurrent tumor of PNET and it could have
triggered the fatal vasospasm [19]. Signaling pathways,
sonic hedgehog (Shh), Wnt, and Notch pathways, espe-
cially the Shh pathway, are considered playing an im-
portant role in the pathogenesis and biological behavior
of desmoplastic PNET [20]. Recent studies indicated in-
appropriate activation of Shh pathway promotes tumori-
genesis and increases the risk of tumor development by
ionizing radiation [21]. Mutations in genes in the Shh
pathway appear to contribute to PNET development.This case is extremely rare in the same parts of the
two different tumors, PNET and LGA. Clinical features
as well as pathological and molecular studies can dis-
criminate PNET from astrocytoma, as these tumors are
clearly different in terms of their origin, typical features
and common characteristics. The pathogenesis of sec-
ondary sPNET is unknown. Whether they represent
transformation of LGA, radiotherapy induced or de novo
tumor is not clear. The possible explanations for occur-
rence of multiple diverse primary brain tumors in cases
that contain two different tumors include secondary
brain tumor induction by radiation, tumorigenetic activ-
ities of certain oncogenes, and defects in tumor suppres-
sor genes [22]. According to the modified Cahan’s
criteria for radiation-induced tumors: the onset of sec-
ondary tumors is sited in the previously irradiated field,
both the primary and secondary tumors are histologi-
cally different from each other, and a sufficiently long la-
tency period [23]. There were two cases tranlated from
low grade gliomas to PNET with pathologic supports,
which might be related to radiotherapy directly, but still
not enough [24]. D. PAL analyzed 12 cases which were
secondary pathological certification in PNET patients
retrospectivly, including 10 cases directly related to radi-
ation therapy, and 2 cases of a direct tumor level change
[17]. The pathological type of this case is also a direct
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the origin. Regardless, the strategy of treatment was still
following the current one. After the secondary surgery,
we performed radiotherapy focused on the tumor pos-
ition. Now 5 months later, we did not see enough evi-
dence of recurrence.
sPNETs are considered as a challenging clinical entity
for neurosurgeons due to its poor prognosis it confers.
Intrinsic biological difference of these tumors has been
suggested by sPNETs patients’ worse outcome in terms
of survival rates in comparison with high risk medullo-
blastoma patients treated by the same therapeutic strat-
egy [9]. The overall 5-year progression-free survival rate
for patients who do not undergo resection ranges from
18 to 47 % [9]. The reported overall survival of PNETs
in the pediatric population varied between 29 and 57 %
[11]. Follow-up ranged from 48 h to 204 months (mean
22.7 months; median 18.7 months) for this summary. 25
patients (62.5 %) were dead, 15 patients were alive. For
all patients, the estimated OS rates were 63.6 % at 1 year,
21.2 % at 2 years, 12.1 % at 3 years, and 6.1 % at 5 years
(Fig. 3, Additional file 1: Table S1). The mean duration
of overall survival (OS) was 22 months. The survival
time differences could be probably attributed to differ-
ences of the tumor sites, growth ways, proliferation dif-
ferentiation degrees and the specific treatments. Maybe
a larger sample-controlled trials is needed. Moreover,
the prognosis for adults with supratentorial PNETs
seems to be worse than that of their pediatricFig. 3 Survival time for 40 sPNET adults in the past decadecounterparts [25]. In adults the most important prog-
nostic factor is considered to be the Ki-67 index. Kim
et al. [4] reported that adult patients with a Ki-67 index
greater than 30 % demonstrated very poor outcome,
with a mean postoperative survival time of eight months
[26]. Mutations in IDH1 were identified in 6 % primary
sPNET [27]. More importantly, in a study by Hayden
et al., it has been suggested that mutations in IDH1, which
encodes for cytoplasmic isocitrate dehydrogenase, are
among the most frequent mutations in sPNET in adult
cases [28]. This case is that no radiotherapy one was ad-
ministrated but transforming from another tumor.
It is not clear whether the occurrence of sPNET in our
patient represent transformation or de novo tumors.
Given the similarity to few previous cases, we postulate
that they are probably radiation induced which should
be considered in differential diagnosis. Molecular abnor-
malities, oncogenes or defective tumor-suppressor genes
of medulloblastomas and astrocytomas patients have re-
cently been investigated; however, corresponding mo-
lecular data of the present patients are unknown. The
potential factors responsible for the development of
multiple primary brain tumors remain unknown, further
studies in elucidating the relevant factors are wanted. In
addition, the more complex multifactors inducing
tumorigenesis have to be clarified in order to resolve the
mechanisms of multiple primary brain tumors. Future
studies in large series may provide reliable data on the
origin and prognostic significance of this component.
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This case is exactly uncertain that reports revelant to trans-
formation from low-grade astrocytoma to a new kind of
tumor or neoplasm induced by radiotation have been pub-
lished. It is not clear whether the occurrence of sPNET in
our patient represent transformation or de novo tumors,
However, radiotherapy was not preformed on the patient
after the primary surgery. This paper is accompanied by a
review of 40 cases of adult sPNET in the past decade, for
all patients, the estimated OS rates were 63.6 % at 1 year,
21.2 % at 2 years, 12.1 % at 3 years, and 6.1 % at 5 years.
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